These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 22197663)

  • 1. Dyslipidemia in PCOS.
    Wild RA
    Steroids; 2012 Mar; 77(4):295-9. PubMed ID: 22197663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome.
    Yilmaz M; Biri A; Bukan N; Karakoç A; Sancak B; Törüner F; Paşaoğlu H
    Gynecol Endocrinol; 2005 May; 20(5):258-63. PubMed ID: 16019370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome.
    Berneis K; Rizzo M; Hersberger M; Rini GB; Di Fede G; Pepe I; Spinas GA; Carmina E
    Int J Clin Pract; 2009 Jan; 63(1):56-62. PubMed ID: 19125993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype.
    Rizzo M; Berneis K; Hersberger M; Pepe I; Di Fede G; Rini GB; Spinas GA; Carmina E
    Hum Reprod; 2009 Sep; 24(9):2286-92. PubMed ID: 19454589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiometabolic abnormalities in the polycystic ovary syndrome: pharmacotherapeutic insights.
    Westerveld HE; Hoogendoorn M; de Jong AW; Goverde AJ; Fauser BC; Dallinga-Thie GM
    Pharmacol Ther; 2008 Sep; 119(3):223-41. PubMed ID: 18602948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid and lipoprotein profile in women with polycystic ovary syndrome.
    Macut D; Panidis D; Glisić B; Spanos N; Petakov M; Bjekić J; Stanojlović O; Rousso D; Kourtis A; Bozić I; Damjanović S
    Can J Physiol Pharmacol; 2008 Apr; 86(4):199-204. PubMed ID: 18418429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of obesity on atherogenic dyslipidemia in women with polycystic ovary syndrome.
    Hernández-Mijares A; Bañuls C; Gómez-Balaguer M; Bergoglio M; Víctor VM; Rocha M
    Eur J Clin Invest; 2013 Jun; 43(6):549-56. PubMed ID: 23528141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dyslipidemia with particular regard to apolipoprotein profile in association with polycystic ovary syndrome: a study among Indian women.
    Maitra A; Pingle RR; Menon PS; Naik V; Gokral JS; Meherji PK
    Int J Fertil Womens Med; 2001; 46(5):271-7. PubMed ID: 11720200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimation of truncal adiposity using waist circumference or the sum of trunk skinfolds: a pilot study for insulin resistance screening in hirsute patients with or without polycystic ovary syndrome.
    Toscani M; Migliavacca R; Sisson de Castro JA; Spritzer PM
    Metabolism; 2007 Jul; 56(7):992-7. PubMed ID: 17570263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High density lipoprotein-associated proteins in non-obese women with and without polycystic ovary syndrome.
    Butler AE; Moin ASM; Reiner Ž; Sathyapalan T; Jamialahmadi T; Sahebkar A; Atkin SL
    Front Endocrinol (Lausanne); 2023; 14():1117761. PubMed ID: 37181037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathophysiology and types of dyslipidemia in PCOS.
    Diamanti-Kandarakis E; Papavassiliou AG; Kandarakis SA; Chrousos GP
    Trends Endocrinol Metab; 2007 Sep; 18(7):280-5. PubMed ID: 17692530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism of triglyceride-rich lipoproteins and lipid transfer to high-density lipoprotein in young obese and normal-weight patients with polycystic ovary syndrome.
    Rocha MP; Maranhão RC; Seydell TM; Barcellos CR; Baracat EC; Hayashida SA; Bydlowski SP; Marcondes JA
    Fertil Steril; 2010 Apr; 93(6):1948-56. PubMed ID: 19765700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How should we manage atherogenic dyslipidemia in women with polycystic ovary syndrome?
    Rizzo M; Berneis K; Carmina E; Rini GB
    Am J Obstet Gynecol; 2008 Jan; 198(1):28.e1-5. PubMed ID: 18166299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dyslipidemia and oxidative stress in PCOS.
    Macut D; Bjekić-Macut J; Savić-Radojević A
    Front Horm Res; 2013; 40():51-63. PubMed ID: 24002405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Activity and distribution of plasma platelet-activating factor acetylhydrolase in polycystic ovary syndrome patients with insulin resistance].
    Wan DH; Fan P; Bai H; Song Q; Liu HW
    Zhonghua Fu Chan Ke Za Zhi; 2010 Jan; 45(1):30-4. PubMed ID: 20367923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LDL species heterogeneity in the atherogenic dyslipidemia of polycystic ovary syndrome.
    Doi SA; Abbas JM; Parkinson L; Chakraborty J; Akanji AO
    Am J Clin Pathol; 2008 May; 129(5):802-10. PubMed ID: 18426742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome.
    Fenkci SM; Fenkci V; Oztekin O; Rota S; Karagenc N
    Hum Reprod; 2008 Jul; 23(7):1602-6. PubMed ID: 18378560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular disease risk factors in polycystic ovary syndrome.
    Dokras A
    Semin Reprod Med; 2008 Jan; 26(1):39-44. PubMed ID: 18181081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dyslipidemia in women with polycystic ovary syndrome: incidence, pattern and predictors.
    Rocha MP; Marcondes JA; Barcellos CR; Hayashida SA; Curi DD; da Fonseca ÂM; Bagnoli VR; Baracat EC
    Gynecol Endocrinol; 2011 Oct; 27(10):814-9. PubMed ID: 20807166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased follistatin levels after oral contraceptive treatment in obese and non-obese women with polycystic ovary syndrome.
    Chen MJ; Yang WS; Chen HF; Kuo JJ; Ho HN; Yang YS; Chen SU
    Hum Reprod; 2010 Mar; 25(3):779-85. PubMed ID: 20093255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.